A Multicenter, Open Labeled, Randomized, Phase III Study Comparing Lopinavir/Ritonavir Plus Atazanavir to Lopinavir/Ritonavir Plus Zidovudine and Lamivudine in Naive HIV-1-Infected Patients: 48-Week Analysis of the LORAN Trial by Ulbricht, K.U et al.
44 The  Open  AIDS  Journal,  2011, 5, 44-50   
 
  1874-6136/11  2011 Bentham Open 
Open Access 
A Multicenter, Open Labeled, Randomized, Phase III Study Comparing 
Lopinavir/Ritonavir Plus Atazanavir to Lopinavir/Ritonavir Plus 
Zidovudine and Lamivudine in Naive HIV-1-Infected Patients: 48-Week 
Analysis of the LORAN Trial 
K.U. Ulbricht
1,§, G.M. Behrens
1,§, M. Stoll
1, B. Salzberger
2, H. Jessen
3, A.B. Jessen
3, B. Kuhlmann
4,  
H. Heiken
4, A. Trein
5 and R.E. Schmidt
*,1 
1Department for Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany 
2Department for Internal Medicine I, University Hospital Regensburg, Germany 
3Private Practice, Berlin, Germany 
4Private Practice, Hannover, Germany 
5Private Practice, Stuttgart, Germany 
Abstract: Objective: The primary aim of the study was to compare the metabolic side effects of a nucleoside analogue-
containing regimen with a nucleoside analogue-sparing double protease inhibitor regimen. A secondary goal was to test 
for efficacy of a double-PI regimen. 
Design: Multicenter, randomized, open-label, phase III clinical trial. 
Subjects: Adult HIV-1-infected individuals naïve to antiretroviral therapy with viral load above 400 HIV-RNA copies/ml 
were randomized (1:1) to either 400 mg lopinavir /100 mg ritonavir (LPV/r) BID plus 150 mg lamivudine/300 mg 
zidovudine (CBV) BID versus LPV/r BID plus 300 mg atazanavir (ATV) QD. Main outcome measure was the virologic 
failure in both groups, defined as viral load 50 copies/ml at week 48. 
Results: In the CBV/LPV/r-arm, 29 out of 35 patients [(83%; 95% confidence interval (CI) 66.9-92.2%] and 18 out of 40 
patients (45%; 95% CI 29.7-61.5%) in the ATV/LPV/r-arm had a HIV-RNA level <50 copies/ml at week 48. The intent-
to-treat analysis revealed inferior virologic response in the ATV/LPV/r arm (Chi-Q and Fisher´s Exact Test p<0.001) and 
resulted in premature termination of the trial. Eleven patients in the ATV/LPV/r-arm discontinued therapy because of 
virological failure. These failures mostly presented with low level replication (<1,000 copies/ml). Increases in CD4 cell 
counts was significantly more rapid in the ATV/LPV/r arm (p=0.02), but comparable at week 48. 
Conclusions: ATV/LPV/r had less virologic efficacy than the conventional RTI-based regimen and resulted in a high 
virological failure rate with low level replication. 
Keywords: HIV-therapy, double-protease-inhibitor, Therapy-naïve patients. 
INTRODUCTION 
  Highly active antiretroviral therapy (HAART) has been 
proven very efficacious for long-term control of viral 
replication and disease progression in HIV-infected 
individuals. The International AIDS Society currently 
recommends standard combination regimens including two 
nucleoside reverse transcriptase inhibitors (NRTI) plus either 
one protease inhibitor (PI) or one non-nucleoside reverse 
transcriptase inhibitors (NNRTI) in therapy-naïve patients 
[1]. Numerous studies provide evidence for the excellent   
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antiviral activity of these combinations and support the 
preferred application in first-line therapy of HIV-infected 
patients. However, conditions, such as adverse side effects 
and virologic failure leading to resistance development, 
constitute major confinements in HIV treatment, thereby 
limiting therapeutic options in a significant number of 
patients. Particularly, peripheral lipoatrophy, hepatic 
steatosis and metabolic disturbances including 
hyperlipidemia, insulin resistance, and lactic acidosis have 
been attributed to both NRTI-and PI-containing regimens [2-
5]. The pathogenesis of these adverse effects during 
antiretroviral therapy has not been fully elucidated yet, but 
mitochondrial toxicity due to thymidine analogues has been 
proposed and replacement of these compounds by alternative 
NRTIs has been demonstrated to result in partial recovery of 
lipoatrophy and lipid disturbances [4-6] and NRTI-sparing 
regimens are now being explored in clinical trials. Double PI in ART-Naïve Patients  The Open AIDS Journal, 2011, Volume 5    45 
  The other major obstacle is the development of viral 
resistance leading to early virologic failure of HIV-therapy. 
This may be due to insufficient adherence, but also virally 
inherited causes or pre-existent mutations may play a role 
[7]. In this regard, resistance due to escape mutations in the 
HIV reverse transcriptase gene is a common phenomenon of 
failing antiretroviral therapy in patients receiving NRTI-
containing HAART. Several studies support the notion that 
regimens containing boosted PIs postpone the incidence of 
NRTI resistance for many years or during the early phases of 
viral rebound. 
  Based on these observations and more recent data [7], 
certain triple NRTI therapies appear to have inferior efficacy 
[1]. 
  The aim of this study was to compare the effects of a 
NRTI-sparing regimen [lopinavir/ritonavir (LPV/r) plus 
atazanavir (ATV)] versus a NRTI-containing regimen 
(LPV/r plus lamivudine and zidovudine) in regard to 
efficacy, toxicity, and metabolic parameters in ARV-naïve 
patients. This national multicenter randomized study 
addresses the following question: Do metabolic parameters, 
clinical side effects and quality of life (QoL) differ between 
a NRTI-containing regimen and a NRTI-sparing regimen? 
Since we assumed the beginning of the study no problems 
with virological efficacy of the regimens, virological 
response was a secondary goal only. 
METHODS 
Subjects and Design 
  The LORAN study was a multicentre randomized, open-
label study in which co-administration of LPV/r and ATV 
(ATV/LPV/r) was compared to LPV/r combined with fixed-
dose combination of zidovudine plus lamivudine in HIV-
positive, antiretroviral-naïve patients. Subjects were 
randomized (1:1) to receive either 400 mg LPV/100 mg 
ritonavir BID (Kaletra
®) plus 150 mg lamivudine/300 mg 
zidovudine BID (Combivir
®, CBV) versus 400 mg 
LPV/100  mg ritonavir (Norvir®) BID plus 300 mg ATV 
(Reyataz
®) QD. A total of 75 subjects were studied for a 
study period of 48 weeks. 
  Inclusion criteria were: HIV-patients at age 18 years, 
naive to antiretroviral therapy, not pregnant or breastfeeding, 
and not having been treated for an active AIDS-defining 
opportunistic infection or receiving any investigational drug 
within 30 days of screening. HIV-RNA level had to be above 
400 copies/ml. Exclusion criteria were severe changes in 
blood count, liver or renal impairment, cardiomyopathy (due 
to any cause) or any significant cardiovascular or 
electrophysiological disease. Baseline data, including 
demographic data, physical and laboratory status, and status 
of disease according to 1993 Centres for Disease Control and 
Prevention classification, were obtained before initiation of 
HAART. All subjects, regardless of treatment assignment, 
returned to the site for a week 4 and week 12 study visit and 
then every 12 weeks until week 48. Procedures at these visits 
included physical examination, vital sign measurements, 
clinical laboratory tests and determinations of antiviral and 
immunologic activity. The study protocol was approved by 
the ethics committee of the Hannover Medical School and by 
the local ethics committees of the investigational sites. The 
study was conducted in accordance with the protocol, ICH 
GCP, regulations governing clinical study conduct, ethical 
principles that have their origin in the Declaration of 
Helsinki, currently 1996 revision and all applicable local 
regulations. All patients gave written informed consent 
before recruitment. The primary endpoints were determined 
as the differences of the NRTI-containing or dual PI regimen 
on metabolic parameters (glucose metabolism, lipid 
paramenters), body fat compositions and quality of life. The 
planned sample size of at least 50 subjects in each treatment 
group provided a 80% power (=0.80) to detect a difference 
in glucose and lipid levels based on the study published by 
Saint-Marc et al. [8]. Assuming metric scale of the relevant 
parameters, normal distribution and similarity of variance in 
both study arms, 50 subjects in each study arm should be 
enough to provide a 80% power to detect differences of 20-
30% for other clinically relevant parameters based on an a 
priori analysis performed with Clinical MEDORA Software. 
  Randomization was performed by means of a predefined 
randomization list (1:1 ratio), using a central randomization 
system (facsimile response) to ensure balance across 
treatment groups in each stratum. Combivir
® and Kaletra
® 
were prescribed by the investigational sites, Reyataz
® was 
bought wholesale and was provided by the Principle 
Investigator. At each study visit, patients underwent routine 
safety monitoring, including hematology and chemistry 
evaluations, CD4 T-cell count, and plasma HIV-RNA levels. 
Measurements were performed at local laboratories. Samples 
for pharmacokinetic measurements were alternating drawn, 
centrifuged, frozen and sent to for further analysis to a 
central lab. Drug monitoring was not regularly performed 
and provided in cases of treatment failure. 
  Monitoring and data collection at the investigational sites 
was performed by Abbott co-workers. An independent Data 
and Safety Monitoring Board had access to the data, 
reviewed the data and performed the statistical analysis at the 
planned interim analysis. 
Study End Points 
  The primary endpoints were determined as the influence 
of NRTI on metabolic parameters and body fat compositions 
and quality of life. The secondary endpoints were the clinical 
side effects, viral suppression at week 48, and immune 
reconstitution at week 48. Virologic failure was defined 
using a sensitive test system (limit of detection <50 HIV-
RNA copies/ml) as either: a) a failure to reach a viral load 
below the detection limit by week 48, or b) a confirmed re-
increase of HIV-RNA from the not measurable to the 
measurable range. 
  A topical interim analyses proved statistical significance 
for the virologic failure in both therapy arms at week 24 with 
a higher rate in the ATV/LPV/r arm than in the CBV/LPV/r 
arm. The statistical calculations were provided by a member 
of the Data Safety Monitoring Bboard (DSMB). The 
statistical difference in the ITT analysis showed p=0.021, the 
observed failures p <0.001, in each case calculated using the 
Fisher's Exact test. Therefore recruitment for this 
prospective, randomized trial was terminated in November 
2006. 
  This of course had enormous consequences for the study. 
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therefore the virological efficacy became the primary focus 
of our study. 
Resistance Determination 
  For resistance determination, viral genotypic assessment 
was performed by Fenner Laboratory, Hamburg, Germany, 
and by the Institute for Virology, University of Cologne, 
Germany, using different algorithms (Geno2Pheno, ANRS, 
Stanford Database). 
 Plasma  viral  load was measured with a commercial kit in 
use in each participating centre or in a cooperating 
laboratory; all had a level of detectability of 50 copies/ml. In 
patients experiencing virologic failure, HIV-1 resistance 
genotyping was performed on frozen plasma samples 
obtained at the time of HIV-RNA increase, in parallel with 
the baseline sample. 
 Pharmacokinetic  measuring was performed by a single 
cooperating laboratory using LC-MS/MS technique. Samples 
for pharmacokinetic measurements were drawn at weeks 4, 
24, 28, and 48 before and three hours after intake of study 
drugs. Sera were frozen at minus 20 °C, collected and sent to 
the principal investigator’s laboratory. In seven subjects in 
the double-PI failures, lopinavir and atazanavir levels were 
measured. 
Statistical Analysis 
  The primary endpoint for which this study was powered 
could not be reached since the study had to be stopped 
prematurely. Therefore the originally secondary endpoint, 
the virological efficacy, became the primary variable to be 
analyzed. Therefore we analyzed the proportion of subjects 
with a plasma HIV-RNA level below 50 copies/ml at week 
48. An intent-to-treat approach was used for this analysis in 
which missing values were considered above 50 copies/ml 
unless the immediately preceding and immediately following 
values are below 50  copies/ml (“non-completer=failure” 
analysis). All values obtained more than one day after study 
drug discontinuation were considered above 50 copies/ml. 
The estimate of the proportion of subjects with HIV-RNA 
levels below 50 copies/ml is provided for each treatment 
arm, along with the corresponding 95% confidence interval 
for the difference in proportions based on the normal 
approximation to the binomial distribution. The proportion 
of patients with HIV-RNA below 50 copies/ml at each visit 
was summarized using an intent-to-treat (missing=failure) 
method, in which all missing values were considered above 
50 copies/ml, an intent-to-treat (last observation carried 
forward) method, in which missing values was replaced by 
the most recent non-missing value, and an observed data 
method, in which missing values were excluded from the 
analysis. Comparisons between treatment arms were 
performed using Fisher’s exact test. Mean changes from 
baseline to each protocol-specified visit were analyzed using 
a one-way analysis of variance (ANOVA) model with 
treatment arm as the only factor. Analyses included all data 
obtained while subjects were on randomized antiretroviral 
therapy. The level of significance was set at p<0.05. 
Statistical analysis was performed using SPSS 16 (SPSS 
Inc., Illinois). 
RESULTS 
Study Population 
  From September 2004 until November 2006, 80 
consecutive HIV-infected HAART-naïve patients at 14 sites 
fulfilled inclusion criteria and were recruited and assigned 
randomly to either treatment arm. Two patients each revoked 
consent prior to and immediately after baseline visit, 
respectively, one was lost to follow up immediately after 
baseline. Seventy-five patients were enrolled in the study 
and began intake of study drugs. The baseline characteristics 
of these 75 patients are provided in Table 1. Patients were 
Table 1.  Baseline Characteristics of Study Population 
 
Baseline Characteristics  All Patients  CBV/LPV/r Group   ATV/LPV/r Group 
Total number  75  35  40 
Female – no. (%)  10 (13.3)  5 (14.3)  5 (12.5) 
Age (years) (Mean (range))  39.1  36.6 (25-65)  41.4 (27-66) 
CD4 count 
Mean 
0-99 cells/mm 
100-199 cells/mm 
200-399 cells/mm 
400 cells/mm 
 
220 
12 
20 
40 
3 
 
239 
5 
7 
21 
2 
 
203 
7 
13 
19 
1 
HIV-1 RNA level 
(Mean (range)) 
log 
<50,000 cop/ml 
50,000-99,999 cop/ml 
100,000-299,999 cop/ml 
300,000 cop/ml 
208,463 
(745-4,200,000) 
5,319 
27 
12 
26 
10 
142,422 
(2,623-548,000) 
5,154 
13 
6 
12 
4 
270,836 
(745-4,200,000) 
5,433 
14 
6 
14 
6 
Clinical category  
       A 
       B 
       C 
 
45 
24 
6 
 
22 
10 
3 
 
23 
14 
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mainly male (13.3 % female), and their mean age was 39 
years. At baseline, the mean plasma HIV-1 RNA level was 
log 5.3 copies/ml, and the mean CD4 cell count was 220 
cells/L. Baseline characteristics were well balanced among 
the two study groups. A total of 29 (83 %) in the CBV/LPV/r 
-arm and 21 (53 %) in the ATV/LPV/r -arm completed the 
protocol until week 48. 
Virologic Response 
  For primary efficiency intent-to treat analysis at week 48, 
29/35 [80%; 95% confidence interval (CI) 66.9-92.2%] of 
patients had a HIV-RNA level below 50 copies/ml in the 
CBV/LPV/r-arm and 18/40 (45%; 95% CI 29.7-61.5%) in the 
ATV/LPV/r-arm, respectively (Fig. 1). This difference was 
statistically significant according to chi-square test and to 
Fisher´s exact test (both p<0.001). When the definition for 
virological failure also considered patients with a detectable 
viral load after previous viral suppression below 50 copies/ml, 
24/35 (69%) of patients receiving CBV/LPV/r had a viral load 
below 50 copies HIV-RNA/mL at week 48, as compared to 
16/40 (40%) in the ATV/LPV/r-arm. When all patients still 
receiving study medication at week 48 were considered 
(observed data analysis), 29/29 (100%) of patients in the 
CBV/LPV/r-arm had a viral load below 50 copies/mL as 
compared to only 18/21 (86%) in the ATV/LPV/r-arm. 
  There was a trend (p=0.077) for delayed time to viral 
suppression in the double-PI-arm. At week 24, 12 of 33 
patients (36%), which were still on study medication, 
continued to have a detectable viral load in the ATV/LPV/r 
arm (range 71-3,420 copies HIV-RAN) as compared to 4 of 
31 patients (13%) receiving drugs in the CBV/LPV/r arm 
(range 53-90 copies HIV-RNA). Of the 12 patients with 
detectable viremia in the ATV/LPV/r arm, 11 had a viral 
load between 50 and 1,000 HIV-RNA copies/ml, but all 
patients with detectable viremia in the CBV/LPV/r arm had 
less than 100 copies HIV-RNA/ml. In addition, 8/33 patients 
(24%) receiving ATV/LPV/r at week 24 had an increasing 
viral load as compared to only 1/31 of patients (3%) treated 
with CBV/LPV/r. Therefore the drug safety monitoring 
board (DSMB) recommended termination of patient 
recruitment. Overall 11 patients in the ATV/LPV/r-arm 
discontinued therapy before week 48 because of virological 
failure, but none of the patients in the CBV/LPV/r-arm. 
  Subsequently nine out of 33 patients still on ATV/LPV/r 
therapy at week 24 were consecutively switched to an 
alternative regimen, but were not followed up until week 48. 
Seven of these nine patients had a rebound in viral load 
before week 36 and before switch. Two out of three patients 
with a detectable viral load in the ATV/LPV/r arm at week 
48 had shown a viral rebound from below 50 copies/ml at 
week 24. Altogether, eleven patients were discontinued due 
to virologic failure, all of them in the ATV/LPV/r arm. In 
agreement with the Drug Safety Monitoring Board, all 
subjects in the ATV/LPV/r arm were offered the possibility 
to switch to CBV/LPV/r independent of virologic success. 
Immunological Response 
  With respect to the immunological response, the increase 
of the CD4+ T cell counts was more rapid up to week 48 in 
the ATV/LPV/r arm (p=0.02) in the “observed data” analysis 
(Fig.  2). At week 48, however, the mean increase from 
baseline was comparable between groups with 151 cells per  
cubic millimetre (standard error of the mean (SEM)) 125.1, 
range -74 – 412) in the ATV/LPV/r group, and 142 (SEM 
99.4, range -171 - 269) in the CBV/LPV/r group, 
respectively (Fig. 2). 
 
Fig. (1). Virologic response. Virologic response as percentage of 
all HIV-1-infected patients with a viral load below 50 copies HIV-
RNA/mL plasma after enrolment into LORAN study (“intend-to-
treat” analysis, top panel) and in all patients receiving antiretroviral 
therapy in both arms (“observed data” analysis, bottom panel). 
Pharmacology and Genotypic Resistance 
  In three out of seven patients with virologic failure 
amplification of HIV was successful. No major genotypic 
changes in HIV-1 protease gene were detected at failure in 
these three patients. Merely, one NRTI resistance (M184IM) 
was detected in a patient receiving ATV/LPV/r. 
Pharmacokinetic measuring showed slightly reduced LPV 
concentrations (2,900 ng/ml) in 1/7 tested subjects in the 
double-PI failures. This patient confirmed wanting 
adherence in the intake of study drugs and had normal 
lopinavir level (4,360 ng/ml) four months later. 
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Fig. (2). Immunologic response. Time course of mean (SEM) CD4 
cell counts (top panel) and mean (SEM) change in CD4 cell counts 
from baseline (buttom panel) in both treatment arms. 
Safety Results 
  In 13 of the 75 patients (17.3 %) toxicity led to 
discontinuation of one or more study drugs occurred; 7/40 
(17.5 %) in the ATV/LPV/r arm and 6/35 (17.1 %) in the 
CBV/LPV/r arm, respectively. Two individuals stopped 
therapy because of diarrhea in the CBV/LPV/r group versus 
one in the ATV/LPV/r group. Three patients in the 
CBV/LPV/r arm suffered from severe nausea and one 
developed anemia. In the ATV/LPV/r group, four patients 
discontinued due to hyperbilirubinemia, one had rash, and 
one was discharged because of hypertriglyceridemia (Table 
2). 
  A total of 8 of 75 patients (10.3 %) presented with new 
grade 3 or 4 clinical or laboratory abnormalities leading to 
hospitalization, but not to termination of study medication. In 
the CBV/LPV/r arm, two patients suffered from gastrointestinal 
discomfort, one developed anemia during co-administration of 
ribavirin for hepatitis C therapy and another one was admitted 
to hospital for an airway infection. In the ATV/LPV/r arm, one 
subject became conspicuous with true sepsis due to a dental 
focus and another one with perineal abscess, which was already 
evident prior to commencement of study drugs. All these 
patients recovered totally. An association could be ruled out for 
each of these events. 
  During the course of the study, two AIDS-defining 
events occurred in the ATV/LPV/r arm, one Pneumocystis 
pneumonia and a case of Non-Hodgkin Lymphoma 20 days 
and three months after baseline visit, respectively. An 
association between the AIDS-defining events and study 
drugs could not be established. One additional patient in the 
ATV/LPV/r arm was diagnosed with progressive multifocal 
leukencephalopathy (PML), but was retrospectively 
classified as having this condition prior to commencement of 
antiretroviral therapy, based on his neurological symptoms. 
None of the patients died during the study. No AIDS-
defining event was observed in the CBV/LPV/r arm. 
  The primary endpoint of this study, metabolic side 
effects, could not be evaluated since the study was 
terminated prematurely. The quality of life data will be 
published elsewhere. 
Table 2.  Treatment Limiting Events and New Grade 3 or 4 Clinical or Laboratory Abnormalities 
 
NRTI Group 
(n=6) 
PI Group 
(n=14) 
NRTI Group 
(n=4) 
PI Group 
(n=4) 
Event 
Treatment-Limiting Event  Grade 3 or 4 Abnormalities 
Virological failure    11
1     
AIDS-defining events        2 
Diarrhea  2  1     
GI-discomfort/Nausea  3    2   
Hyperbilirubinemia    4     
Anemia  1    1   
Rash    1     
Hypertriglyceridemia    1     
Others
2      1  2 
1p=0.0008; 
2including, airway infection, sepsis, perineal abscess. 
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DISCUSSION 
  Our study was originally laid out to examine metabolic 
effects as well as quality of life of two different therapy 
regimens in HIV-infected, therapy-naive patients and to 
compare with each other. 80 of 100 originally planned patients 
were enrolled into the study and alternating assigned either to 
the double-PI arm including ATV/LPV/r (Reyataz
® and 
Kaletra
®) or to conventional CBV/LPV/r (Combivir
® and 
Kaletra
®) in the control group. 
  In an interim analysis, 24-week data were evaluated for 
virologic and immunological course of a total of 48 patients. In 
the study protocol the virologic failure was defined as a virus 
load above 50 copies HIV-RNA/mL by week 48. 
  Several factors may influence the virologic response to 
antiretroviral treatment, in particular potency, tolerability, and 
adherence [7,9]. Regarding tolerability, more patients developed 
gastrointestinal adverse events in the CBV/LPV/r arm, whereas 
hyperbilirubinemia was only seen in the ATV/LPV/r arm. 
Considering that pharmacokinetic measurements revealed no 
significantly reduced protease inhibitor levels in patients with 
failing dual PI regime this would not argue for reduced 
adherence as underlying cause. However, one should consider 
that possible adherence issue were not specifically captured, 
since we did not evaluate adherence by either patient self-report 
of adherence, pill counts or electronic measurement devices. It 
is important to note that the intend-to-treat analysis virological 
failure as end point considers all patients that stopped 
medication for whatever reason. Although this restrictive 
estimation is preferred in many clinical trails, since it gives a 
better assessment of the clinical efficacy of the treatment 
regimens, it can be misleading in terms of the virological 
reasons for treatment failures with either increase in viral load 
or resistance mutation development. This is particularly 
important, given that our study medication was not blinded, 
which could lead to even further bias in adverse event reporting 
and viral efficacy judgement. This is also relevant when looking 
at the “as-treated” analysis. This examination ignores all 
patients discontinuing because of insufficient virological 
efficiency and therefore tends to overestimate the virologic 
potency. As can be seen in our results, an “as-treated” analysis 
considerably reduced the differences in response rates between 
both arms. We wish to point out that in the ATV/LPV/r arm 11 
patients switched therapy because of true virological failure and 
conclude from this that the dual PI arm performed definitely 
inferior to the CBV/LPV/r arm in terms of achieving a viral 
load below 50 copies/mL. 
  Due to antiviral potency, the NRTI-sparing regimen of 
atazanavir and ritonavir boosted lopinavir demonstrated less 
virologic efficacy than the conventional NRTI-based regimen in 
this study. The mechanism is not clear, but most likely at least 
two classes of antiretroviral drugs are required particularly in 
the initial treatment of HIV-1 infection, when viral replication is 
high [10-13]. Potentially, co-administration of two protease 
inhibitors is not beneficial or synergistically active due to 
competitive effector mechanisms. Similar results were found in 
the 2IP ANRS 127 trial, where two different PI-combinations 
showed delayed virologic response in therapy-naïve patients 
[14]. Furthermore, the MONARK trial demonstrated lower rates 
of virologic suppression in lopinavir/ritonavir mono-therapy 
compared with lopinavir/ritonavir and a conventional NRTI-
backbone in therapy-naïve patients [15,16]. Although it has 
been shown that a NRTI-sparing regimen is more likely 
associated with drug resistance [7], an alternative explanation 
for the lower rate of complete virological response in the dual 
PI-arm could be that these drugs act later in the virus life cycle. 
Using a mathematical model to investigate the effects of various 
drug classes on the dynamics of HIV-1 decay, Sedaghat et al. 
[17] have shown that the stage at which a drug acts affects the 
dynamics of viral decay. They predicted that the drug class 
acting latest in the viral life cycle dictates the dynamics of HIV-
1 decay and found that the later in the life cycle an inhibitor 
acts, the more rapid the decay in viremia was. 
  We wish to emphasize that several points should to be 
considered in regard to the resistance testing. Our study is 
limited by the fact that we had only small numbers of sample 
available for successful resistance mutation analysis. Previous 
trails have shown that patients may develop viral rebound or fail 
to achieve a viral load below 50 copies in regimens containing 
PIs without viral resistance mutations. Although this can be 
considered as an advantage, since there is frequently no 
resistance mutation detectable in regions encoding for the 
protease as well as other relevant regions encoding for reverse 
transcriptase, this does not exclude resistance mutation 
development in regions of the virus that are not routinely 
assessed. Second, in only three out of seven patients with 
detectable viral load in the double-PI arm we were able to 
amplify sufficient material for sequence analysis and can not 
make firm conclusions on the overall resistance mutation 
development. Third, the detection of vial RNA could reflect 
release of HIV-RNA from latently infected cells and does not 
necessarily correlate to viral evolution and increasing viral 
replication. Finally, it could be possible that the detectable 
viremia is a result of release of HIV-RNA from pharmaco-
logically “sanctuary sites” such as the central nervous system, 
where complete suppression is not achieved for pharmaco-
logical reasons. We do not know, whether the HIV-1 replicative 
capacity is reduced in our patients with virologic failure and 
persistent LLV, as suggested by other studies [17-19]. The 
extent of the decline in viral fitness, however, may be limited as 
HIV may eventually evade the selective pressure of a drug [20]. 
  Nevertheless, dual PI regimen could be evaluated as an 
option in patients for a maintenance regimen. Consistent with 
this option, LPV/r mono-therapy in the OK-04 study showed 
that lopinavir/ritonavir mono-therapy can maintain HIV viral 
suppression in a very large proportion of patients [21] and 
similar outcomes were obtained with darunavir/r as single agent 
[22]. However, this may not apply for all protease inhibitors and 
depend on pretreatment [23]. The different immunological 
response with greater increase in CD4 cells in our study may be 
explained by myelosuppressive mechanisms by zidovudine. 
Furthermore, antiapoptotic effects on CD4 cells have been 
suggested for HIV-1 protease inhibitors, which are independent 
of the antiviral effects [24]. 
  The previous objectives of this study to examine the effect 
of a NRTI sparing regimen on toxicity and metabolic 
parameters  versus a NRTI containing regimen could not be 
reached due to early discontinuation. Once it became evident 
that the double-PI regimen of ATV/LPV/r was inferior with 
regard to virologic response compared to CBV/LPV/r, we 
stopped recruitment of study patients. Patients with virological 
failure were switched to the CBV/LPV/r regimen or another 
standard ART regimen. 50    The Open AIDS Journal, 2011, Volume 5  Ulbricht et al. 
  In summary, our study revealed that the dual PI regimen 
comprising ATV/LPV/r had less virologic efficacy in an intent-
to-treat analysis of therapy naïve HIV-patients than the convent-
ional RTI-based regimen. As already shown by Landman et al. 
[14] dual protease inhibitor regimens were insufficient to 
rapidly suppress plasma HIV-RNA to less than 50 copies/mL in 
antiretroviral-naïve patients. Therefore protease inhibitor mono-
therapy strategies may be useful rather for simplification of 
HAART in patients with suppressed HIV-RNA. 
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